Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment

Cytomegalovirus infection causes significant morbidity and mortality in congenitally-infected infants and transplant recipients. There is no licensed vaccine for CMV, and antiviral treatment of CMV infection is challenged by drug toxicities and emergence of resistant CMV isolates in treated patients. New approaches for both prevention and treatment would have a substantial public health impact in both populations, but numerous challenges have hampered progress in these areas.

Congenital CMV infection is the most common infectious cause of disability in newborn infants. It results in brain damage/developmental delays, and sensorineural hearing loss, and is an occasional cause of mortality. Approximately 13.5% of congenitally-infected newborns are symptomatic. Nearly 50% of symptomatic and 10% of asymptomatic infants develop some degree of hearing loss, and a large proportion of symptomatic infants suffer of some degree of psychomotor and cognitive disabilities, with visual impairment in up to half of symptomatic infants. Congenital CMV infection occurs in between 0.2% and 0.7% of newborns in the United States and other developed nations, with even higher prevalence in the developing world. Infants carried by seronegative pregnant women acutely infected in pregnancy are at particularly high risk, with up to 32% of primary maternal infections leading to congenital CMV transmission.

CMV infection also causes significant morbidity and mortality in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients, including viremia with associated end-organ diseases, graft rejection, graft failure and, in HSCT patients, graft-versus-host disease. Post-transplant antiviral therapy has reduced the severity of CMV disease and associated mortality rates, but long-term treatment is required, and late onset CMV disease occurs in a significant number of patients after completion of the standard course of antiviral therapy.

This meeting will review the current state of knowledge of CMV disease, including which populations may be most affected, and challenges associated with current diagnostic platforms. The meeting will also facilitate the discovery and development of vaccines and therapeutics for serious CMV infections and/or disease by assessing the state of the art and identifying knowledge gaps and other barriers to advancement of products.

Registration may not guarantee you a seat in the main conference space, but instead a seat in an adjacent overflow room where the program will be webcast.


Details

  • When

  • Tuesday, September 4, 2018 - Thursday, September 6, 2018
    8:00 AM - 5:00 PM
    Eastern Time

  • Where

  • Fishers Lane Conference Center, Room 1D13
    5601 Fishers Lane
    Rockville, Maryland 20852
    USA

Additional Information

Non-American citizen attendees of this workshop must undergo foreign security clearance in order to gain entrance into the conference center. If you are not an American citizen, please email Liane Agulto at agultol@niaid.nih.gov immediately upon registration to initiate foreign clearance. Please allow no less than 2 weeks for clearance prior to arriving at our conference center.
 
Security:
Visitors must enter the building through the front lobby entrance on Fishers Lane after 7:00 a.m. A valid, government-issued photo ID (if you are an international visitor, your passport) must be presented to the security guards. Security screenings are required for anyone not in possession of a valid HHS badge. Because visitor badges are "location-defined," all on-site attendees MUST register for the conference.
 
Parking: Parking is available in the Atlantic Services Parking garage located at 12721 Twinbrook Parkway. The entrance to the garage is on Twinbrook Parkway between Fishers Lane and Halpine Drive.  The garage can also be reached by turning left at the first access road on Fishers Lane (you will see a sign for Atlantic Parking on the sidewalk).  The cost is $3 for the first hour, $5 for the second hour, and $8 for all day.
 
Public Transportation: 5601 Fishers Lane is serviced by Ride On bus and Metro Map. The nearest Metro station is Twinbrook (Red Line), which is 1/2 mile away from the building. Cross Twinbrook Parkway at the intersection with Fishers Lane and proceed down Fishers Lane. 5601 is at the end on the left. 
 
The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top